Cannabis effects on brain structure, function, and cognition: considerations for medical uses of cannabis and its derivatives

References

• Piluzza G, Delogu G, Cabras A, Marceddu S, Bullitta S. Differentiation between fiber and drug types of hemp (Cannabis sativa L.) from a collection of wild and domesticated accessions. Genet Resour Crop Evol. 2013;60:2331–42. doi:10.1007/s10722-013-0001-5.
   Web of Science ®Google Scholar
• Andre CM, Hausman J-F, Guerriero G. Cannabis sativa: the Plant of the thousand and one molecules. Front Plant Sci. 2016;7:19. doi:10.3389/fpls.2016.00019.
   PubMed Web of Science ®Google Scholar
• Pellati F, Brighenti V, Sperlea J, et al. New methods for the comprehensive analysis of bioactive compounds in Cannabis sativa L. (hemp) . Mol Basel Switz. 2018;23.
   Google Scholar
• U.S. Department of Health and Human Services. National survey on drug use and health [Internet]. Rockville, MD: Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality; 2018. Available from: https://datafiles.samhsa.gov/.
   Google Scholar
• Djeungoue-Petga M-A, Hebert-Chatelain E. Linking mitochondria and synaptic transmission: the CB1 receptor. BioEssays News Rev Mol Cell Dev Biol. 2017;39.
   Google Scholar
• Mackie K. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol. 2008;20:10–14. doi:10.1111/j.1365-2826.2008.01671.x.
   PubMed Web of Science ®Google Scholar
• Straiker AJ, Maguire G, Mackie K, et al. Localization of cannabinoid CB1 receptors in the human anterior eye and retina. Invest Ophthalmol Vis Sci. 1999;40:2442–48.
   PubMed Web of Science ®Google Scholar
• Bilkei-Gorzo A. The endocannabinoid system in normal and pathological brain ageing. Philos Trans R Soc Lond B Biol Sci. 2012;367:3326–41. doi:10.1098/rstb.2011.0388.
   PubMed Web of Science ®Google Scholar
• Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev. 2003;83:1017–66. doi:10.1152/physrev.00004.2003.
   PubMed Web of Science ®Google Scholar
• Regehr WG, Carey MR, Best AR. Activity-dependent regulation of synapses by retrograde messengers. Neuron. 2009;63:154–70. doi:10.1016/j.neuron.2009.06.021.
   PubMed Web of Science ®Google Scholar
• Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 1997;77:299–318. doi:10.1016/S0306-4522(96)00428-9.
   PubMed Web of Science ®Google Scholar
• Befort K. Interactions of the opioid and cannabinoid systems in reward: insights from knockout studies. Front Pharmacol. 2015;6:6.
   PubMed Web of Science ®Google Scholar
• Egerton A, Allison C, Brett RR, Pratt JA. Cannabinoids and prefrontal cortical function: insights from preclinical studies. Neurosci Biobehav Rev. 2006;30:680–95. doi:10.1016/j.neubiorev.2005.12.002.
   PubMed Web of Science ®Google Scholar
• Katona I, Freund TF. Multiple functions of endocannabinoid signaling in the brain. Annu Rev Neurosci. 2012;35:529–58. doi:10.1146/annurev-neuro-062111-150420.
   PubMed Web of Science ®Google Scholar
• Hill MN, McEwen BS. Involvement of the endocannabinoid system in the neurobehavioural effects of stress and glucocorticoids. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:791–97. doi:10.1016/j.pnpbp.2009.11.001.
   PubMed Web of Science ®Google Scholar
• Diao X, Huestis MA. New synthetic cannabinoids metabolism and strategies to best identify optimal marker metabolites. Front Chem. 2019;7:109. doi:10.3389/fchem.2019.00109.
   PubMed Web of Science ®Google Scholar
• Bloomfield MAP, Hindocha C, Green SF, Wall MB, Lees R, Petrilli K, Costello H, Ogunbiyi MO, Bossong MG, Freeman TP. The neuropsychopharmacology of cannabis: A review of human imaging studies. Pharmacol Ther. 2019;195:132–61. doi:10.1016/j.pharmthera.2018.10.006.
   PubMed Web of Science ®Google Scholar
• Burns HD, Van Laere K, Sanabria-Bohórquez S, Hamill TG, Bormans G, Eng W-S, Gibson R, Ryan C, Connolly B, Patel S, et al. [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci USA. 2007;104:9800–05. doi:10.1073/pnas.0703472104.
   PubMed Web of Science ®Google Scholar
• Zhang H-Y, Gao M, Liu Q-R, Bi G-H, Li X, Yang H-J, Gardner EL, Wu J, Xi Z-X. Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proc Natl Acad Sci USA. 2014;111:E5007–5015. doi:10.1073/pnas.1413210111.
   PubMed Web of Science ®Google Scholar
• Rodriguez JJ, Mackie K, Pickel VM. Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J Neurosci Off J Soc Neurosci. 2001;21:823–33. doi:10.1523/JNEUROSCI.21-03-00823.2001.
   PubMed Web of Science ®Google Scholar
• Díaz-Alonso J, Guzmán M, Galve-Roperh I. Endocannabinoids via CB₁ receptors act as neurogenic niche cues during cortical development. Philos Trans R Soc Lond B Biol Sci. 2012;367:3229–41. doi:10.1098/rstb.2011.0385.
   PubMed Web of Science ®Google Scholar
• Friedrich J, Khatib D, Parsa K, Santopietro A, Gallicano GI. The grass isn’t always greener: the effects of cannabis on embryological development. BMC Pharmacol Toxicol. 2016;17:45. doi:10.1186/s40360-016-0085-6.
   PubMed Web of Science ®Google Scholar
• Huizink AC. Prenatal cannabis exposure and infant outcomes: overview of studies. Prog Neuropsychopharmacol Biol Psychiatry. 2014;52:45–52. doi:10.1016/j.pnpbp.2013.09.014.
   PubMed Web of Science ®Google Scholar
• Crews F, He J, Hodge C. Adolescent cortical development: a critical period of vulnerability for addiction. Pharmacol Biochem Behav. 2007;86:189–99. doi:10.1016/j.pbb.2006.12.020.
   PubMed Web of Science ®Google Scholar
• Giedd JN. Structural magnetic resonance imaging of the adolescent brain. Ann N Y Acad Sci. 2004;1021:77–85. doi:10.1196/annals.1308.009.
   PubMed Web of Science ®Google Scholar
• Wakeford AGP, Wetzell BB, Pomfrey RL, Clasen MM, Taylor WW, Hempel BJ, Riley AL. The effects of cannabidiol (CBD) on Δ9-tetrahydrocannabinol (THC) self-administration in male and female Long-Evans rats. Exp Clin Psychopharmacol. 2017;25:242–48. doi:10.1037/pha0000135.
   PubMed Web of Science ®Google Scholar
• Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153:199–215. doi:10.1038/bjp.2008.22.
   PubMed Web of Science ®Google Scholar
• Martínez-Pinilla E, Varani K, Reyes-Resina I, Angelats E, Vincenzi F, Ferreiro-Vera C, Oyarzabal J, Canela EI, Lanciego JL, Nadal X, et al. Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors. Front Pharmacol. 2017;8:744. doi:10.3389/fphar.2017.00744.
   PubMed Web of Science ®Google Scholar
• Morales P, Reggio PH, Jagerovic N. An overview on medicinal chemistry of synthetic and natural derivatives of cannabidiol. Front Pharmacol. 2017;8:422. doi:10.3389/fphar.2017.00422.
   PubMed Web of Science ®Google Scholar
• Navarro G, Reyes-Resina I, Rivas-Santisteban R, Sánchez de Medina V, Morales P, Casano S, Ferreiro-Vera C, Lillo A, Aguinaga D, Jagerovic N, et al. Cannabidiol skews biased agonism at cannabinoid CB1 and CB2 receptors with smaller effect in CB1-CB2 heteroreceptor complexes. Biochem Pharmacol. 2018;157:148–58. doi:10.1016/j.bcp.2018.08.046.
   PubMed Web of Science ®Google Scholar
• Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol. 2007;150:613–23. doi:10.1038/sj.bjp.0707133.
   PubMed Web of Science ®Google Scholar
• Tham M, Yilmaz O, Alaverdashvili M, Kelly MEM, Denovan-Wright EM, Laprairie RB. Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. Br J Pharmacol. 2019;176:1455–69. doi:10.1111/bph.14440.
   PubMed Web of Science ®Google Scholar
• Kathmann M, Flau K, Redmer A, Tränkle C, Schlicker E. Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn. Schmiedebergs Arch. Pharmacol. 2006;372:354–61. doi:10.1007/s00210-006-0033-x.
   PubMed Web of Science ®Google Scholar
• Dornbush RL, Freedman AM. Chronic cannabis use: introduction. Ann N Y Acad Sci. 1976;282:vii–viii. doi:10.1111/nyas.1976.282.issue-1.
   PubMed Web of Science ®Google Scholar
• Hollister LE. Health aspects of cannabis. Pharmacol Rev. 1986;38:1–20.
   PubMed Web of Science ®Google Scholar
• Hollister LE. Health aspects of cannabis: revisited. Int J Neuropsychopharmacol. 1998;1:71–80. doi:10.1017/S1461145798001060.
   PubMed Web of Science ®Google Scholar
• Iversen L. Cannabis and the brain. Brain J Neurol. 2003;126:1252–70. doi:10.1093/brain/awg143.
   Web of Science ®Google Scholar
• Batalla A, Bhattacharyya S, Yücel M, Fusar-Poli P, Crippa JA, Nogué S, Torrens M, Pujol J, Farré M, Martin-Santos R, et al. Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. PLoS One. 2013;8:e55821. doi:10.1371/journal.pone.0055821.
   PubMed Web of Science ®Google Scholar
• Lorenzetti V, Chye Y, Silva P, Solowij N, Roberts CA. Does regular cannabis use affect neuroanatomy? An updated systematic review and meta-analysis of structural neuroimaging studies. Eur Arch Psychiatry Clin Neurosci. 2019;269:59–71. doi:10.1007/s00406-019-00979-1.
   PubMed Web of Science ®Google Scholar
• Egertová M, Elphick MR. Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB. J Comp Neurol. 2000;422:159–71. doi:10.1002/(SICI)1096-9861(20000626)422:2<159::AID-CNE1>3.0.CO;2-1.
   PubMed Web of Science ®Google Scholar
• Katona I, Rancz EA, Acsady L, Ledent C, Mackie K, Hájos N, Freund TF. Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci Off J Soc Neurosci. 2001;21:9506–18. doi:10.1523/JNEUROSCI.21-23-09506.2001.
   PubMed Web of Science ®Google Scholar
• Nader DA, Sanchez ZM. Effects of regular cannabis use on neurocognition, brain structure, and function: a systematic review of findings in adults. Am J Drug Alcohol Abuse. 2018;44:4–18. doi:10.1080/00952990.2017.1306746.
   PubMed Web of Science ®Google Scholar
• Ashtari M, Avants B, Cyckowski L, Cervellione KL, Roofeh D, Cook P, Gee J, Sevy S, Kumra S. Medial temporal structures and memory functions in adolescents with heavy cannabis use. J Psychiatr Res. 2011;45:1055–66. doi:10.1016/j.jpsychires.2011.01.004.
   PubMed Web of Science ®Google Scholar
• Battistella G, Fornari E, Annoni J-M, Chtioui H, Dao K, Fabritius M, Favrat B, Mall J-F, Maeder P, Giroud C. Long-term effects of cannabis on brain structure. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2014;39:2041–48. doi:10.1038/npp.2014.67.
   PubMed Web of Science ®Google Scholar
• Burggren AC, Siddarth P, Mahmood Z, London ED, Harrison TM, Merrill DA, Small GW, Bookheimer SY. Subregional hippocampal thickness abnormalities in older adults with a history of heavy cannabis use. Cannabis Cannabinoid Res. 2018;3:242–51. doi:10.1089/can.2018.0035.
   PubMedGoogle Scholar
• Yücel M, Lorenzetti V, Suo C, Zalesky A, Fornito A, Takagi MJ, Lubman DI, Solowij N. Hippocampal harms, protection and recovery following regular cannabis use. Transl Psychiatry. 2016;6:e710. doi:10.1038/tp.2015.201.
   PubMed Web of Science ®Google Scholar
• Yücel M, Solowij N, Respondek C, et al. Regional brain abnormalities associated with long-term heavy cannabis use. Arch Gen Psychiatry. 2008;65:694–701.
   PubMed Web of Science ®Google Scholar
• Demirakca T, Sartorius A, Ende G, et al. Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol. Drug Alcohol Depend. 2011;114:242–45.
   PubMed Web of Science ®Google Scholar
• Matochik JA, Eldreth DA, Cadet J-L, Bolla KI. Altered brain tissue composition in heavy marijuana users. Drug Alcohol Depend. 2005;77:23–30. doi:10.1016/j.drugalcdep.2004.06.011.
   PubMed Web of Science ®Google Scholar
• Tzilos GK, Cintron CB, Wood JBR, Simpson NS, Young AD, Pope HG, Yurgelun-Todd DA. Lack of hippocampal volume change in long-term heavy cannabis users. Am J Addict. 2005;14:64–72. doi:10.1080/10550490590899862.
   PubMed Web of Science ®Google Scholar
• Koenders L, Lorenzetti V, de Haan L, Suo C, Vingerhoets W, van Den Brink W, Wiers RW, Meijer CJ, Machielsen M, Goudriaan AE, et al. Longitudinal study of hippocampal volumes in heavy cannabis users. J Psychopharmacol Oxf Engl. 2017;31:1027–34. doi:10.1177/0269881117718380.
   PubMed Web of Science ®Google Scholar
• Chye Y, Lorenzetti V, Suo C, Batalla A, Cousijn J, Goudriaan AE, Jenkinson M, Martin‐Santos R, Whittle S, Yücel M, et al. Alteration to hippocampal volume and shape confined to cannabis dependence: a multi-site study. Addict Biol. 2019;24:822–34. doi:10.1111/adb.2019.24.issue-4.
   PubMed Web of Science ®Google Scholar
• Lopez-Quintero C, Pérez de Los Cobos J, Hasin DS, Okuda M, Wang S, Grant BF, Blanco C. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 2011;115:120–30. doi:10.1016/j.drugalcdep.2010.11.004.
   PubMed Web of Science ®Google Scholar
• Lorenzetti V, Lubman DI, Whittle S, Solowij N, Yücel M. Structural MRI findings in long-term cannabis users: what do we know?. Subst Use Misuse. 2010;45:1787–808. doi:10.3109/10826084.2010.482443.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Compton WM, Weiss SRB. Adverse health effects of marijuana use. N Engl J Med. 2014;371:879. doi:10.1056/NEJMoa1410490.
   PubMed Web of Science ®Google Scholar
• Mokrysz C, Freeman TP, Korkki S, Griffiths K, Curran HV. Are adolescents more vulnerable to the harmful effects of cannabis than adults? A placebo-controlled study in human males. Transl Psychiatry. 2016;6:e961. doi:10.1038/tp.2016.225.
   PubMed Web of Science ®Google Scholar
• Jager G, Ramsey NF. Long-term consequences of adolescent cannabis exposure on the development of cognition, brain structure and function: an overview of animal and human research. Curr Drug Abuse Rev. 2008;1:114–23. doi:10.2174/1874473710801020114.
   PubMedGoogle Scholar
• Cousijn J, Wiers RW, Ridderinkhof KR, van Den Brink W, Veltman DJ, Goudriaan AE. Grey matter alterations associated with cannabis use: results of a VBM study in heavy cannabis users and healthy controls. NeuroImage. 2012;59:3845–51. doi:10.1016/j.neuroimage.2011.09.046.
   PubMed Web of Science ®Google Scholar
• Gilman JM, Kuster JK, Lee S, Lee MJ, Kim BW, Makris N, van der Kouwe A, Blood AJ, Breiter HC. Cannabis use is quantitatively associated with nucleus accumbens and amygdala abnormalities in young adult recreational users. J Neurosci Off J Soc Neurosci. 2014;34:5529–38. doi:10.1523/JNEUROSCI.4745-13.2014.
   PubMed Web of Science ®Google Scholar
• Koenders L, Cousijn J, Vingerhoets WAM, van Den Brink W, Wiers RW, Meijer CJ, Machielsen MWJ, Veltman DJ, Goudriaan AE, de Haan L, et al. grey matter changes associated with heavy cannabis use: a longitudinal sMRI study. PLoS One. 2016;11:e0152482. doi:10.1371/journal.pone.0152482.
   PubMed Web of Science ®Google Scholar
• Moreno-Alcázar A, Gonzalvo B, Canales-Rodríguez EJ, Blanco L, Bachiller D, Romaguera A, Monté-Rubio GC, Roncero C, McKenna PJ, Pomarol-Clotet E. Larger Gray matter volume in the basal ganglia of heavy Cannabis users detected by voxel-based morphometry and subcortical volumetric analysis. Front Psychiatry. 2018;9:175. doi:10.3389/fpsyt.2018.00175.
   PubMed Web of Science ®Google Scholar
• Weiland BJ, Thayer RE, Depue BE, Sabbineni A, Bryan AD, Hutchison KE. Daily marijuana use is not associated with brain morphometric measures in adolescents or adults. J Neurosci Off J Soc Neurosci. 2015;35:1505–12. doi:10.1523/JNEUROSCI.2946-14.2015.
   PubMed Web of Science ®Google Scholar
• Pagliaccio D, Barch DM, Bogdan R, Wood PK, Lynskey MT, Heath AC, Agrawal A. Shared predisposition in the association between cannabis use and subcortical brain structure. JAMA Psychiatry. 2015;72:994–1001. doi:10.1001/jamapsychiatry.2015.1054.
   PubMed Web of Science ®Google Scholar
• Gillespie NA, Neale MC, Bates TC, Eyler LT, Fennema-Notestine C, Vassileva J, Lyons MJ, Prom-Wormley EC, McMahon KL, Thompson PM, et al. Testing associations between cannabis use and subcortical volumes in two large population-based samples. Addict Abingdon Engl. 2018. doi:10.1111/add.v113.9.
   Google Scholar
• Arnone D, Barrick TR, Chengappa S, Mackay CE, Clark CA, Abou-Saleh MT. Corpus callosum damage in heavy marijuana use: preliminary evidence from diffusion tensor tractography and tract-based spatial statistics. NeuroImage. 2008;41:1067–74. doi:10.1016/j.neuroimage.2008.02.064.
   PubMed Web of Science ®Google Scholar
• Becker MP, Collins PF, Lim KO, Muetzel RL, Luciana M. Longitudinal changes in white matter microstructure after heavy cannabis use. Dev Cogn Neurosci. 2015;16:23–35. doi:10.1016/j.dcn.2015.10.004.
   PubMed Web of Science ®Google Scholar
• Gruber SA, Silveri MM, Dahlgren MK, Yurgelun-Todd D. Why so impulsive? White matter alterations are associated with impulsivity in chronic marijuana smokers. Exp Clin Psychopharmacol. 2011;19:231–42. doi:10.1037/a0023034.
   PubMed Web of Science ®Google Scholar
• Zalesky A, Solowij N, Yücel M, Lubman DI, Takagi M, Harding IH, Lorenzetti V, Wang R, Searle K, Pantelis C, et al. Effect of long-term cannabis use on axonal fibre connectivity. Brain J Neurol. 2012;135:2245–55. doi:10.1093/brain/aws136.
   Web of Science ®Google Scholar
• Filbey F, Yezhuvath U. Functional connectivity in inhibitory control networks and severity of cannabis use disorder. Am J Drug Alcohol Abuse. 2013;39:382–91. doi:10.3109/00952990.2013.841710.
   PubMed Web of Science ®Google Scholar
• Price JS, McQueeny T, Shollenbarger S, Browning EL, Wieser J, Lisdahl KM. Effects of marijuana use on prefrontal and parietal volumes and cognition in emerging adults. Psychopharmacology (Berl.). 2015;232:2939–50. doi:10.1007/s00213-015-3931-0.
   PubMed Web of Science ®Google Scholar
• Lorenzetti V, Alonso-Lana S, Youssef GJ, et al. Adolescent Cannabis use: what is the evidence for functional brain alteration?. Curr Pharm Des. 2016;22:6353–65.
   PubMed Web of Science ®Google Scholar
• Scott JC, Rosen AFG, Moore TM, Roalf DR, Satterthwaite TD, Calkins ME, Ruparel K, Gur RE, Gur RC. Cannabis use in youth is associated with limited alterations in brain structure. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2019;44:1362–69. doi:10.1038/s41386-019-0347-2.
   PubMed Web of Science ®Google Scholar
• Orr C, Spechler P, Cao Z, Albaugh M, Chaarani B, Mackey S, D’Souza D, Allgaier N, Banaschewski T, Bokde ALW, et al. Grey matter volume differences associated with extremely low levels of cannabis use in adolescence. J Neurosci Off J Soc Neurosci. 2019;39:1817–27. doi:10.1523/JNEUROSCI.3375-17.2018.
   PubMed Web of Science ®Google Scholar
• Hasin DS, Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, Jung J, Pickering RP, Ruan WJ, Smith SM, et al. Prevalence of Marijuana use disorders in the United States between 2001-2002 and 2012-2013. JAMA Psychiatry. 2015;72:1235–42. doi:10.1001/jamapsychiatry.2015.1858.
   PubMed Web of Science ®Google Scholar
• Mauro PM, Carliner H, Brown QL, Hasin DS, Shmulewitz D, Rahim-Juwel R, Sarvet AL, Wall MM, Martins SS. Age differences in daily and nondaily Cannabis use in the United States, 2002-2014. J Stud Alcohol Drugs. 2018;79:423–31. doi:10.15288/jsad.2018.79.423.
   PubMed Web of Science ®Google Scholar
• Kim D-J, Schnakenberg Martin AM, Shin Y-W, Jo HJ, Cheng H, Newman SD, Sporns O, Hetrick WP, Calkins E, O’Donnell BF. Aberrant structural-functional coupling in adult cannabis users. Hum Brain Mapp. 2019;40:252–61. doi:10.1002/hbm.v40.1.
   PubMed Web of Science ®Google Scholar
• Sagar KA, Gruber SA. Interactions between recreational cannabis use and cognitive function: lessons from functional magnetic resonance imaging. Ann. N Y Acad Sci. 2018. doi:10.1111/nyas.13990.
   PubMed Web of Science ®Google Scholar
• Yanes JA, Riedel MC, Ray KL, Kirkland AE, Bird RT, Boeving ER, Reid MA, Gonzalez R, Robinson JL, Laird AR, et al. Neuroimaging meta-analysis of cannabis use studies reveals convergent functional alterations in brain regions supporting cognitive control and reward processing. J Psychopharmacol Oxf Engl. 2018;32:283–95. doi:10.1177/0269881117744995.
   PubMed Web of Science ®Google Scholar
• Atakan Z, Bhattacharyya S, Allen P, Martín-Santos R, Crippa JA, Borgwardt SJ, Fusar-Poli P, Seal M, Sallis H, Stahl D, et al. Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers. Psychol Med. 2013;43:1255–67. doi:10.1017/S0033291712001924.
   PubMed Web of Science ®Google Scholar
• Harding IH, Solowij N, Harrison BJ, Takagi M, Lorenzetti V, Lubman DI, Seal ML, Pantelis C, Yücel M. Functional connectivity in brain networks underlying cognitive control in chronic cannabis users. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2012;37:1923–33. doi:10.1038/npp.2012.39.
   PubMed Web of Science ®Google Scholar
• Chang L, Yakupov R, Cloak C, Ernst T. Marijuana use is associated with a reorganized visual-attention network and cerebellar hypoactivation. Brain J Neurol. 2006;129:1096–112. doi:10.1093/brain/awl064.
   Web of Science ®Google Scholar
• Jager G, Kahn RS, Van Den Brink W, Van Ree JM, Ramsey NF. Long-term effects of frequent cannabis use on working memory and attention: an fMRI study. Psychopharmacology (Berl.). 2006;185:358–68. doi:10.1007/s00213-005-0298-7.
   PubMed Web of Science ®Google Scholar
• Jager G, Van Hell HH, De Win MML, Kahn RS, Van Den Brink W, Van Ree JM, Ramsey NF. Effects of frequent cannabis use on hippocampal activity during an associative memory task. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2007;17:289–97. doi:10.1016/j.euroneuro.2006.10.003.
   PubMed Web of Science ®Google Scholar
• Kanayama G, Rogowska J, Pope HG, Gruber SA, Yurgelun-Todd DA. Spatial working memory in heavy cannabis users: a functional magnetic resonance imaging study. Psychopharmacology (Berl.). 2004;176:239–47. doi:10.1007/s00213-004-1885-8.
   PubMed Web of Science ®Google Scholar
• Bechara A, Tranel D, Damasio H. Characterization of the decision-making deficit of patients with ventromedial prefrontal cortex lesions. Brain J Neurol. 2000;123:2189–202. doi:10.1093/brain/123.11.2189.
   Web of Science ®Google Scholar
• Nestor L, Hester R, Garavan H. Increased ventral striatal BOLD activity during non-drug reward anticipation in cannabis users. NeuroImage. 2010;49:1133–43. doi:10.1016/j.neuroimage.2009.07.022.
   PubMed Web of Science ®Google Scholar
• Vaidya JG, Block RI, O’Leary DS, Ponto LB, Ghoneim MM, Bechara A. Effects of chronic marijuana use on brain activity during monetary decision-making. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2012;37:618–29. doi:10.1038/npp.2011.227.
   PubMed Web of Science ®Google Scholar
• Wesley MJ, Hanlon CA, Porrino LJ. Poor decision-making by chronic marijuana users is associated with decreased functional responsiveness to negative consequences. Psychiatry Res. 2011;191:51–59. doi:10.1016/j.pscychresns.2010.10.002.
   PubMed Web of Science ®Google Scholar
• King GR, Ernst T, Deng W, Stenger A, Gonzales RMK, Nakama H, Chang L. Altered brain activation during visuomotor integration in chronic active cannabis users: relationship to cortisol levels. J Neurosci Off J Soc Neurosci. 2011;31:17923–31. doi:10.1523/JNEUROSCI.4148-11.2011.
   PubMed Web of Science ®Google Scholar
• Gruber SA, Rogowska J, Yurgelun-Todd DA. Altered affective response in marijuana smokers: an FMRI study. Drug Alcohol Depend. 2009;105:139–53. doi:10.1016/j.drugalcdep.2009.05.022.
   PubMed Web of Science ®Google Scholar
• Bourque J, Mendrek A, Durand M, Lakis N, Lipp O, Stip E, Lalonde P, Grignon S, Potvin S. Cannabis abuse is associated with better emotional memory in schizophrenia: a functional magnetic resonance imaging study. Psychiatry Res. 2013;214:24–32. doi:10.1016/j.pscychresns.2013.05.012.
   PubMed Web of Science ®Google Scholar
• Lichenstein SD, Musselman S, Shaw DS, Sitnick S, Forbes EE. Nucleus accumbens functional connectivity at age 20 is associated with trajectory of adolescent cannabis use and predicts psychosocial functioning in young adulthood. Addict Abingdon Engl. 2017;112:1961–70. doi:10.1111/add.v112.11.
   PubMed Web of Science ®Google Scholar
• Chang L, Chronicle EP. Functional imaging studies in cannabis users. Neurosci Rev J Bringing Neurobiol Neurol Psychiatry. 2007;13:422–32.
   Google Scholar
• Cheng H, Skosnik PD, Pruce BJ, Brumbaugh MS, Vollmer JM, Fridberg DJ, O’Donnell BF, Hetrick WP, Newman SD. Resting state functional magnetic resonance imaging reveals distinct brain activity in heavy cannabis users - a multi-voxel pattern analysis. J Psychopharmacol Oxf Engl. 2014;28:1030–40. doi:10.1177/0269881114550354.
   PubMed Web of Science ®Google Scholar
• Pujol J, Blanco-Hinojo L, Batalla A, López-Solà M, Harrison BJ, Soriano-Mas C, Crippa JA, Fagundo AB, Deus J, de la Torre R, et al. Functional connectivity alterations in brain networks relevant to self-awareness in chronic cannabis users. J Psychiatr Res. 2014;51:68–78. doi:10.1016/j.jpsychires.2013.12.008.
   PubMed Web of Science ®Google Scholar
• Manza P, Tomasi D, Volkow ND. Subcortical local functional hyperconnectivity in cannabis dependence. Biol Psychiatry Cogn Neurosci Neuroimaging. 2018;3:285–93. doi:10.1016/j.bpsc.2017.11.012.
   PubMedGoogle Scholar
• Cuttler C, McLaughlin RJ, Graf P. Mechanisms underlying the link between cannabis use and prospective memory. PLoS One. 2012;7:e36820. doi:10.1371/journal.pone.0036820.
   PubMed Web of Science ®Google Scholar
• Solowij N, Jones KA, Rozman ME, Davis SM, Ciarrochi J, Heaven PCL, Lubman DI, Yücel M. Verbal learning and memory in adolescent cannabis users, alcohol users and non-users. Psychopharmacology (Berl.). 2011;216:131–44. doi:10.1007/s00213-011-2203-x.
   PubMed Web of Science ®Google Scholar
• Moreno M, Estevez AF, Zaldivar F, Montes JMG, Gutiérrez-Ferre VE, Esteban L, Sánchez-Santed F, Flores P. Impulsivity differences in recreational cannabis users and binge drinkers in a university population. Drug Alcohol Depend. 2012;124:355–62. doi:10.1016/j.drugalcdep.2012.02.011.
   PubMed Web of Science ®Google Scholar
• Solowij N, Jones KA, Rozman ME, Davis SM, Ciarrochi J, Heaven PCL, Pesa N, Lubman DI, Yücel M. Reflection impulsivity in adolescent cannabis users: a comparison with alcohol-using and non-substance-using adolescents. Psychopharmacology (Berl.). 2012;219:575–86. doi:10.1007/s00213-011-2486-y.
   PubMed Web of Science ®Google Scholar
• Whitlow CT, Liguori A, Livengood LB, Hart SL, Mussat-Whitlow BJ, Lamborn CM, Laurienti PJ, Porrino LJ. Long-term heavy marijuana users make costly decisions on a gambling task. Drug Alcohol Depend. 2004;76:107–11. doi:10.1016/j.drugalcdep.2004.04.009.
   PubMed Web of Science ®Google Scholar
• Verdejo-Garcia A, Benbrook A, Funderburk F, David P, Cadet J-L, Bolla KI. The differential relationship between cocaine use and marijuana use on decision-making performance over repeat testing with the Iowa Gambling Task. Drug Alcohol Depend. 2007;90:2–11. doi:10.1016/j.drugalcdep.2007.02.004.
   PubMed Web of Science ®Google Scholar
• Gilman JM, Calderon V, Curran MT, Hopfer CJ, Mikulich-Gilbertson SK. Young adult cannabis users report greater propensity for risk-taking only in non-monetary domains. Drug Alcohol Depend. 2015;147:26–31. doi:10.1016/j.drugalcdep.2014.12.004.
   PubMed Web of Science ®Google Scholar
• Becker B, Wagner D, Gouzoulis-Mayfrank E, Spuentrup E, Daumann J. The impact of early-onset cannabis use on functional brain correlates of working memory. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:837–45. doi:10.1016/j.pnpbp.2010.03.032.
   PubMed Web of Science ®Google Scholar
• Jager G, Block RI, Luijten M, et al. Cannabis use and memory brain function in adolescent boys: a cross-sectional multicenter functional magnetic resonance imaging study. J Am Acad Child Adolesc Psychiatry. 2010;49:561–572, 572.e1-3.
   PubMed Web of Science ®Google Scholar
• Abdullaev Y, Posner MI, Nunnally R, Dishion TJ. Functional MRI evidence for inefficient attentional control in adolescent chronic cannabis abuse. Behav Brain Res. 2010;215:45–57. doi:10.1016/j.bbr.2010.06.023.
   PubMed Web of Science ®Google Scholar
• Cousijn J, Wiers RW, Ridderinkhof KR, van Den Brink W, Veltman DJ, Porrino LJ, Goudriaan AE. Individual differences in decision making and reward processing predict changes in cannabis use: a prospective functional magnetic resonance imaging study. Addict Biol. 2013;18:1013–23. doi:10.1111/adb.2013.18.issue-6.
   PubMed Web of Science ®Google Scholar
• Behan B, Connolly CG, Datwani S, Doucet M, Ivanovic J, Morioka R, Stone A, Watts R, Smyth B, Garavan H. Response inhibition and elevated parietal-cerebellar correlations in chronic adolescent cannabis users. Neuropharmacology. 2014;84:131–37. doi:10.1016/j.neuropharm.2013.05.027.
   PubMed Web of Science ®Google Scholar
• Block RI, O’Leary DS, Hichwa RD, Augustinack JC, Boles Ponto LL, Ghoneim MM, Arndt S, Hurtig RR, Watkins GL, Hall JA, et al. Effects of frequent marijuana use on memory-related regional cerebral blood flow. Pharmacol Biochem Behav. 2002;72:237–50. doi:10.1016/S0091-3057(01)00771-7.
   PubMed Web of Science ®Google Scholar
• Bolla KI, Eldreth DA, Matochik JA, CADET J. Neural substrates of faulty decision-making in abstinent marijuana users. NeuroImage. 2005;26:480–92. doi:10.1016/j.neuroimage.2005.02.012.
   PubMed Web of Science ®Google Scholar
• Bogaty SER, Lee RSC, Hickie IB, Hermens DF. Meta-analysis of neurocognition in young psychosis patients with current cannabis use. J Psychiatr Res. 2018;99:22–32. doi:10.1016/j.jpsychires.2018.01.010.
   PubMed Web of Science ®Google Scholar
• Gonzalez R, Pacheco-Colón I, Duperrouzel JC, Hawes SW. Does Cannabis use cause declines in neuropsychological functioning? A Review of longitudinal studies. J Int Neuropsychol Soc JINS. 2017;23:893–902. doi:10.1017/S1355617717000789.
   PubMed Web of Science ®Google Scholar
• Cosker E, Schwitzer T, Ramoz N, Ligier F, Lalanne L, Gorwood P, Schwan R, Laprévote V. The effect of interactions between genetics and cannabis use on neurocognition. Review Prog Neuropsychopharmacol Biol Psychiatry. 2018;82:95–106. doi:10.1016/j.pnpbp.2017.11.024.
   PubMed Web of Science ®Google Scholar
• Crane NA, Schuster RM, Gonzalez R. Preliminary evidence for a sex-specific relationship between amount of cannabis use and neurocognitive performance in young adult cannabis users. J Int Neuropsychol Soc JINS. 2013;19:1009–15. doi:10.1017/S135561771300088X.
   PubMed Web of Science ®Google Scholar
• Liem-Moolenaar M, Te Beek ET, de Kam ML, Franson KL, Kahn RS, Hijman R, Touw D, van Gerven JM. Central nervous system effects of haloperidol on THC in healthy male volunteers. J Psychopharmacol Oxf Engl. 2010;24:1697–708. doi:10.1177/0269881109358200.
   PubMed Web of Science ®Google Scholar
• Metrik J, Kahler CW, Reynolds B, McGeary JE, Monti PM, Haney M, de Wit H, Rohsenow DJ. Balanced placebo design with marijuana: pharmacological and expectancy effects on impulsivity and risk taking. Psychopharmacology (Berl.). 2012;223:489–99. doi:10.1007/s00213-012-2740-y.
   PubMed Web of Science ®Google Scholar
• Morrison PD, Zois V, McKeown DA, Jennaway M, Basudewa IDG, Taylor R. The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med. 2009;39:1607–16. doi:10.1017/S0033291708004893.
   PubMed Web of Science ®Google Scholar
• Ramaekers JG, Kauert G, van Ruitenbeek P, Theunissen EL, Schneider E, Moeller MR. High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2006;31:2296–303. doi:10.1038/sj.npp.1301068.
   PubMed Web of Science ®Google Scholar
• Ramaekers JG, Moeller MR, van Ruitenbeek P, Theunissen EL, Schneider E, Kauert G. Cognition and motor control as a function of Delta9-THC concentration in serum and oral fluid: limits of impairment. Drug Alcohol Depend. 2006;85:114–22. doi:10.1016/j.drugalcdep.2006.03.015.
   PubMed Web of Science ®Google Scholar
• Weinstein A, Brickner O, Lerman H, Greemland M, Bloch M, Lester H, Chisin R, Sarne Y, Mechoulam R, Bar-Hamburger R, et al. A study investigating the acute dose-response effects of 13 mg and 17 mg Delta 9- tetrahydrocannabinol on cognitive-motor skills, subjective and autonomic measures in regular users of marijuana. J Psychopharmacol Oxf Engl. 2008;22:441–51. doi:10.1177/0269881108088194.
   PubMed Web of Science ®Google Scholar
• Anderson BM, Rizzo M, Block RI, Pearlson GD, O’Leary DS. Sex, drugs, and cognition: effects of marijuana. J Psychoact Drugs. 2010;42:413–24. doi:10.1080/02791072.2010.10400704.
   PubMed Web of Science ®Google Scholar
• Ramaekers JG, Kauert G, Theunissen EL, Toennes SW, Moeller MR. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J Psychopharmacol Oxf Engl. 2009;23:266–77. doi:10.1177/0269881108092393.
   PubMed Web of Science ®Google Scholar
• Ranganathan M, Carbuto M, Braley G, Elander J, Perry E, Pittman B, Radhakrishnan R, Sewell RA, D’Souza DC. Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans. Int J Neuropsychopharmacol. 2012;15:1251–64. doi:10.1017/S1461145711001830.
   PubMed Web of Science ®Google Scholar
• Theunissen EL, Heckman P, de Sousa Fernandes Perna EB, Kuypers KPC, Sambeth A, Blokland A, Prickaerts J, Toennes SW, Ramaekers JG. Rivastigmine but not vardenafil reverses cannabis-induced impairment of verbal memory in healthy humans. Psychopharmacology (Berl). 2015;232:343–53. doi:10.1007/s00213-014-3667-2.
   PubMed Web of Science ®Google Scholar
• Crane NA, Schuster RM, Fusar-Poli P, et al. Effects of cannabis on neurocognitive functioning: recent advances, neurodevelopmental influences, and sex differences. Neuropsychol Rev. 2013;23:117–37.
   PubMed Web of Science ®Google Scholar
• Dougherty DM, Mathias CW, Dawes MA, Furr RM, Charles NE, Liguori A, Shannon EE, Acheson A. Impulsivity, attention, memory, and decision-making among adolescent marijuana users. Psychopharmacology (Berl.). 2013;226:307–19. doi:10.1007/s00213-012-2908-5.
   PubMed Web of Science ®Google Scholar
• Gonzalez R, Schuster RM, Mermelstein RJ, Vassileva J, Martin EM, Diviak KR. Performance of young adult cannabis users on neurocognitive measures of impulsive behavior and their relationship to symptoms of cannabis use disorders. J Clin Exp Neuropsychol. 2012;34:962–76. doi:10.1080/13803395.2012.703642.
   PubMed Web of Science ®Google Scholar
• Grant JE, Chamberlain SR, Schreiber L, Odlaug BL. Neuropsychological deficits associated with cannabis use in young adults. Drug Alcohol Depend. 2012;121:159–62. doi:10.1016/j.drugalcdep.2011.08.015.
   PubMed Web of Science ®Google Scholar
• Lisdahl KM, Price JS. Increased marijuana use and gender predict poorer cognitive functioning in adolescents and emerging adults. J Int Neuropsychol Soc JINS. 2012;18:678–88. doi:10.1017/S1355617712000276.
   PubMed Web of Science ®Google Scholar
• Rogers RD, Wakeley J, Robson PJ, Bhagwagar Z, Makela P. The effects of low doses of delta-9 tetrahydrocannabinol on reinforcement processing in the risky decision-making of young healthy adults. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2007;32:417–28. doi:10.1038/sj.npp.1301175.
   PubMed Web of Science ®Google Scholar
• Lane SD, Cherek DR, Tcheremissine OV, Lieving LM, Pietras CJ. Acute marijuana effects on human risk taking. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2005;30:800–09. doi:10.1038/sj.npp.1300620.
   PubMed Web of Science ®Google Scholar
• Vadhan NP, Hart CL, van Gorp WG, Gunderson EW, Haney M, Foltin RW. Acute effects of smoked marijuana on decision making, as assessed by a modified gambling task, in experienced marijuana users. J Clin Exp Neuropsychol. 2007;29:357–64. doi:10.1080/13803390600693615.
   PubMed Web of Science ®Google Scholar
• Schmetzer AD. Book review: cannabis and cognitive functioning, by Nadia Solowij. Ann Clin Psychiatry. 2000;12:254–57. doi:10.1023/A:1009051030174.
   Google Scholar
• Solowij N, Battisti R. The chronic effects of cannabis on memory in humans: a review. Curr Drug Abuse Rev. 2008;1:81–98. doi:10.2174/1874473710801010081.
   PubMedGoogle Scholar
• Solowij N, Stephens R, Roffman RA, et al. Does marijuana use cause long-term cognitive deficits?. JAMA. 2002;287:2653–2654; author reply 2654.
   Google Scholar
• Fontes MA, Bolla KI, Cunha PJ, Almeida PP, Jungerman F, Laranjeira RR, Bressan RA, Lacerda ALT. Cannabis use before age 15 and subsequent executive functioning. Br J Psychiatry J Ment Sci. 2011;198:442–47. doi:10.1192/bjp.bp.110.077479.
   PubMed Web of Science ®Google Scholar
• Hester R, Nestor L, Garavan H. Impaired error awareness and anterior cingulate cortex hypoactivity in chronic cannabis users. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2009;34:2450–58. doi:10.1038/npp.2009.67.
   PubMed Web of Science ®Google Scholar
• Tait RJ, Mackinnon A, Christensen H. Cannabis use and cognitive function: 8-year trajectory in a young adult cohort. Addict Abingdon Engl. 2011;106:2195–203. doi:10.1111/j.1360-0443.2011.03574.x.
   PubMed Web of Science ®Google Scholar
• Jackson NJ, Isen JD, Khoddam R, Irons D, Tuvblad C, Iacono WG, McGue M, Raine A, Baker LA. Impact of adolescent marijuana use on intelligence: results from two longitudinal twin studies. Proc Natl Acad Sci USA. 2016;113:E500–508. doi:10.1073/pnas.1516648113.
   PubMed Web of Science ®Google Scholar
• Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RSE, McDonald K, Ward A, Poulton R, Moffitt TE. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA. 2012;109:E2657–2664. doi:10.1073/pnas.1206820109.
   PubMed Web of Science ®Google Scholar
• Mokrysz C, Freeman TP, Commentary on Meier, et al. 2018: smoke and mirrors-are adolescent cannabis users vulnerable to cognitive impairment? Addict Abingdon Engl. 2018;113:266–67. doi:10.1111/add.14055.
   PubMed Web of Science ®Google Scholar
• Fletcher PC, Honey GD. Schizophrenia, ketamine and cannabis: evidence of overlapping memory deficits. Trends Cogn Sci. 2006;10:167–74. doi:10.1016/j.tics.2006.02.008.
   PubMed Web of Science ®Google Scholar
• Ranganathan M, D’Souza DC. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl.). 2006;188:425–44. doi:10.1007/s00213-006-0508-y.
   PubMed Web of Science ®Google Scholar
• Solowij N, Pesa N. [Cognitive abnormalities and cannabis use]. Rev Bras Psiquiatr Sao Paulo Braz. 2010;32:S31–40.
   PubMed Web of Science ®Google Scholar
• Broyd SJ, van Hell HH, Beale C, Yücel M, Solowij N. Acute and chronic effects of cannabinoids on human cognition-a systematic review. Biol Psychiatry. 2016;79:557–67. doi:10.1016/j.biopsych.2015.12.002.
   PubMed Web of Science ®Google Scholar
• Ganzer F, Bröning S, Kraft S, Sack P-M, Thomasius R. Weighing the evidence: a systematic review on long-term neurocognitive effects of Cannabis use in abstinent adolescents and adults. Neuropsychol Rev. 2016;26:186–222. doi:10.1007/s11065-016-9316-2.
   PubMed Web of Science ®Google Scholar
• Thames AD, Arbid N, Sayegh P. Cannabis use and neurocognitive functioning in a non-clinical sample of users. Addict Behav. 2014;39:994–99. doi:10.1016/j.addbeh.2014.01.019.
   PubMed Web of Science ®Google Scholar
• Wagner D, Becker B, Gouzoulis-Mayfrank E, Daumann J. Interactions between specific parameters of cannabis use and verbal memory. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:871–76. doi:10.1016/j.pnpbp.2010.04.004.
   PubMed Web of Science ®Google Scholar
• Morgan CJA, Gardener C, Schafer G, Swan S, Demarchi C, Freeman TP, Warrington P, Rupasinghe I, Ramoutar A, Tan N, et al. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol Med. 2012;42:391–400. doi:10.1017/S0033291711001322.
   PubMed Web of Science ®Google Scholar
• Solowij N, Stephens RS, Roffman RA, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA. 2002;287:1123–31.
   PubMed Web of Science ®Google Scholar
• Bilkei-Gorzo A, Albayram O, Draffehn A, Sanjiv K, Myrberg IH, Paulin CBJ, Heshmati Y, Hagenkort A, Kutzner J, Page BDG, et al. A chronic low dose of Δ9-tetrahydrocannabinol (THC) restores cognitive function in old mice. Nat Med. 2017;23:782–87. doi:10.1038/nm.4265.
   PubMed Web of Science ®Google Scholar
• Martín-Moreno AM, Brera B, Spuch C, Carro E, García-García L, Delgado M, Pozo MA, Innamorato NG, Cuadrado A, de Ceballos ML. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation. 2012;9:8. doi:10.1186/1742-2094-9-8.
   PubMed Web of Science ®Google Scholar
• Ramírez BG, Blázquez C, Gómez Del Pulgar T, et al. Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci Off J Soc Neurosci. 2005;25:1904–13.
   PubMed Web of Science ®Google Scholar
• Osborne AL, Solowij N, Weston-Green K. A systematic review of the effect of cannabidiol on cognitive function: relevance to schizophrenia. Neurosci Biobehav Rev. 2017;72:310–24. doi:10.1016/j.neubiorev.2016.11.012.
   PubMed Web of Science ®Google Scholar
• Calabrese EJ, Rubio-Casillas A. Biphasic effects of THC in memory and cognition. Eur J Clin Invest. 2018;48:e12920. doi:10.1111/eci.2018.48.issue-5.
   PubMed Web of Science ®Google Scholar
• Levine A, Clemenza K, Rynn M, Lieberman J. Evidence for the risks and consequences of adolescent Cannabis exposure. J Am Acad Child Adolesc Psychiatry. 2017;56:214–25. doi:10.1016/j.jaac.2016.12.014.
   PubMed Web of Science ®Google Scholar
• Lisdahl KM, Wright NE, Kirchner-Medina C, Maple KE, Shollenbarger S. Considering Cannabis: the effects of regular Cannabis use on neurocognition in adolescents and young adults. Curr Addict Rep. 2014;1:144–56. doi:10.1007/s40429-014-0019-6.
   PubMedGoogle Scholar
• Meier MH, Caspi A, Danese A, Fisher HL, Houts R, Arseneault L, Moffitt TE. Associations between adolescent cannabis use and neuropsychological decline: a longitudinal co-twin control study. Addict Abingdon Engl. 2018;113:257–65. doi:10.1111/add.v113.2.
   PubMed Web of Science ®Google Scholar
• Mokrysz C, Landy R, Gage SH, Munafò MR, Roiser JP, Curran HV. Are IQ and educational outcomes in teenagers related to their cannabis use? A prospective cohort study. J Psychopharmacol Oxf Engl. 2016;30:159–68. doi:10.1177/0269881115622241.
   PubMed Web of Science ®Google Scholar
• Becker MP, Collins PF, Luciana M. Neurocognition in college-aged daily marijuana users. J Clin Exp Neuropsychol. 2014;36:379–98. doi:10.1080/13803395.2014.893996.
   PubMed Web of Science ®Google Scholar
• Fridberg DJ, Queller S, Ahn W-Y, Kim W, Bishara AJ, Busemeyer JR, Porrino L, Stout JC. Cognitive mechanisms underlying risky decision-making in chronic Cannabis users. J Math Psychol. 2010;54:28–38. doi:10.1016/j.jmp.2009.10.002.
   PubMed Web of Science ®Google Scholar
• Schuster RM, Gilman J, Schoenfeld D, et al. One month of Cannabis abstinence in adolescents and young adults is associated with improved memory. J Clin Psychiatry. 2018;79.
   Web of Science ®Google Scholar
• Medina KL, Hanson KL, Schweinsburg AD, COHEN-ZION M, NAGEL BJ, TAPERT SF. Neuropsychological functioning in adolescent marijuana users: subtle deficits detectable after a month of abstinence. J Int Neuropsychol Soc JINS. 2007;13:807–20. doi:10.1017/S1355617707071032.
   PubMed Web of Science ®Google Scholar
• Winward JL, Hanson KL, Tapert SF, Brown SA. Heavy alcohol use, marijuana use, and concomitant use by adolescents are associated with unique and shared cognitive decrements. J Int Neuropsychol Soc JINS. 2014;20:784–95. doi:10.1017/S1355617714000666.
   PubMed Web of Science ®Google Scholar
• Hooper SR, Woolley D, De Bellis MD. Intellectual, neurocognitive, and academic achievement in abstinent adolescents with cannabis use disorder. Psychopharmacology (Berl.). 2014;231:1467–77. doi:10.1007/s00213-014-3463-z.
   PubMed Web of Science ®Google Scholar
• Pope HG, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry. 2001;58:909–15. doi:10.1001/archpsyc.58.10.909.
   PubMed Web of Science ®Google Scholar
• Schreiner AM, Dunn ME. Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: a meta-analysis. Exp Clin Psychopharmacol. 2012;20:420–29. doi:10.1037/a0029117.
   PubMed Web of Science ®Google Scholar
• Scott JC, Slomiak ST, Jones JD, Rosen AFG, Moore TM, Gur RC. Association of Cannabis with cognitive functioning in adolescents and young adults: a systematic review and meta-analysis. JAMA Psychiatry. 2018;75:585–95. doi:10.1001/jamapsychiatry.2018.0335.
   PubMed Web of Science ®Google Scholar
• Colizzi M, Bhattacharyya S. Does Cannabis composition matter? Differential effects of delta-9-tetrahydrocannabinol and Cannabidiol on human cognition. Curr Addict Rep. 2017;4:62–74. doi:10.1007/s40429-017-0142-2.
   PubMedGoogle Scholar
• Ciccone CD. Medical Marijuana: just the Beginning of a long, strange trip?. Phys Ther. 2017;97:239–48.
   PubMed Web of Science ®Google Scholar
• Curran HV, Freeman TP, Mokrysz C, Lewis DA, Morgan CJA, Parsons LH. Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci. 2016;17:293–306. doi:10.1038/nrn.2016.28.
   PubMed Web of Science ®Google Scholar
• Karila L, Roux P, Rolland B, Benyamina A, Reynaud M, Aubin H-J, Lancon C. Acute and long-term effects of cannabis use: a review. Curr Pharm Des. 2014;20:4112–18. doi:10.2174/13816128113199990620.
   PubMed Web of Science ®Google Scholar
• Leung L. Cannabis and its derivatives: review of medical use. J Am Board Fam Med JABFM. 2011;24:452–62. doi:10.3122/jabfm.2011.04.100280.
   PubMed Web of Science ®Google Scholar
• Franz CA, Frishman WH. Marijuana use and Cardiovascular disease. Cardiol Rev. 2016;24:158–62. doi:10.1097/CRD.0000000000000103.
   PubMed Web of Science ®Google Scholar
• Sidney S. Cardiovascular consequences of marijuana use. J Clin Pharmacol. 2002;42:64S–70S.
   PubMed Web of Science ®Google Scholar
• Biehl JR, Burnham EL. Cannabis smoking in 2015: a concern for lung health? Chest. 2015;148:596–606. doi:10.1378/chest.15-0447.
   PubMed Web of Science ®Google Scholar
• Papatheodorou SI, Buettner H, Rice MB, Mittleman MA. Recent marijuana use and associations with exhaled nitric oxide and pulmonary function in adults in the United States. Chest. 2016;149:1428–35. doi:10.1016/j.chest.2015.12.033.
   PubMed Web of Science ®Google Scholar
• Sagar KA, Gruber SA. Marijuana matters: reviewing the impact of marijuana on cognition, brain structure and function, & exploring policy implications and barriers to research. Int Rev Psychiatry Abingdon Engl. 2018;30:251–67. doi:10.1080/09540261.2018.1460334.
   PubMed Web of Science ®Google Scholar
• Gruber SA, Sagar KA, Dahlgren MK, Yao X, Levine SJ. Splendor in the Grass? A pilot study assessing the impact of medical Marijuana on executive function. Front Pharmacol. 2016;7:355. doi:10.3389/fphar.2016.00323.
   PubMed Web of Science ®Google Scholar
• Hyder AA, Wunderlich CA, Puvanachandra P, et al. The impact of traumatic brain injuries: a global perspective. NeuroRehabilitation. 2007;22:341–53.
   PubMed Web of Science ®Google Scholar
• Sun J-H, Tan L, Yu J-T. Post-stroke cognitive impairment: epidemiology, mechanisms and management. Ann Transl Med. 2014;2:80.
   PubMedGoogle Scholar
• Grundy RI. The therapeutic potential of the cannabinoids in neuroprotection. Expert Opin Investig Drugs. 2002;11:1365–74. doi:10.1517/13543784.11.10.1365.
   PubMed Web of Science ®Google Scholar
• Latorre JGS, Schmidt EB. Cannabis, Cannabinoids, and cerebral metabolism: potential applications in stroke and disorders of the central nervous system. Curr Cardiol Rep. 2015;17:627. doi:10.1007/s11886-015-0627-3.
   PubMed Web of Science ®Google Scholar
• Magid L, Heymann S, Elgali M, Millis SR, Scott C, Pearson C. Role of CB2 receptor in the recovery of mice after traumatic brain injury. J Neurotrauma. 2019;36:1836–46. doi:10.1089/neu.2018.5873.
   PubMed Web of Science ®Google Scholar
• Shohami E, Cohen-Yeshurun A, Magid L, Facciolo F, Rendina EA, Page C, Cazzola M, Orlandi A. Endocannabinoids and traumatic brain injury. Br J Pharmacol. 2011;163:1402–10. doi:10.1111/j.1476-5381.2011.01339.x.
   PubMed Web of Science ®Google Scholar
• Hussain S, Sankar R. Pharmacologic treatment of intractable epilepsy in children: a syndrome-based approach. Semin Pediatr Neurol. 2011;18:171–78. doi:10.1016/j.spen.2011.06.003.
   PubMed Web of Science ®Google Scholar
• Wirrell EC. Treatment of Dravet Syndrome. Can J Neurol Sci J Can Sci Neurol. 2016;43:S13–18. doi:10.1017/cjn.2016.249.
   PubMed Web of Science ®Google Scholar
• Szaflarski JP, Bebin EM. Cannabis, cannabidiol, and epilepsy–from receptors to clinical response. Epilepsy Behav EB. 2014;41:277–82. doi:10.1016/j.yebeh.2014.08.135.
   PubMed Web of Science ®Google Scholar
• Hussain SA, Zhou R, Jacobson C, Weng J, Cheng E, Lay J, Hung P, Lerner JT, Sankar R. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome. Epilepsy Behav EB. 2015;47:138–41. doi:10.1016/j.yebeh.2015.04.009.
   PubMed Web of Science ®Google Scholar
• Sirven JI. Cannabis, cannabidiol, and epilepsies: the truth is somewhere in the middle. Epilepsy Behav EB. 2014;41:270–71. doi:10.1016/j.yebeh.2014.09.006.
   PubMed Web of Science ®Google Scholar
• Cilio MR, Thiele EA, Devinsky O. The case for assessing cannabidiol in epilepsy. Epilepsia. 2014;55:787–90. doi:10.1111/epi.2014.55.issue-6.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, Miller I, Flamini R, Wilfong A, Filloux F, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15:270–78. doi:10.1016/S1474-4422(15)00379-8.
   PubMed Web of Science ®Google Scholar
• Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Lond Engl. 2018;391:1085–96. doi:10.1016/S0140-6736(18)30136-3.
   PubMed Web of Science ®Google Scholar
• McCoy B, Wang L, Zak M, Al‐Mehmadi S, Kabir N, Alhadid K, McDonald K, Zhang G, Sharma R, Whitney R, et al. A prospective open-label trial of a CBD/THC cannabis oil in dravet syndrome. Ann Clin Transl Neurol. 2018;5:1077–88. doi:10.1002/acn3.2018.5.issue-9.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017;376:2011–20. doi:10.1056/NEJMoa1611618.
   PubMed Web of Science ®Google Scholar
• Mitchell JT, Sweitzer MM, Tunno AM, Kollins SH, McClernon FJ, Lidzba K. “I use weed for my ADHD”: A qualitative analysis of online forum discussions on Cannabis use and ADHD. PLoS One. 2016;11:e0156614. doi:10.1371/journal.pone.0156614.
   PubMed Web of Science ®Google Scholar
• Ferner M Number of children seeking medical Marijuana soars in Colorado [Internet]. HuffPost. Available from: https://www.huffpost.com/entry/medical-marijuana-children_n_4768219.
   Google Scholar
• Hadland SE, Knight JR, Harris SK. Medical marijuana: review of the science and implications for developmental-behavioral pediatric practice. J Dev Behav Pediatr JDBP. 2015;36:115–23. doi:10.1097/DBP.0000000000000129.
   PubMed Web of Science ®Google Scholar
• Rasmussen J, Casey BJ, van Erp TGM, Tamm L, Epstein JN, Buss C, Bjork JM, Molina BSG, Velanova K, Mathalon DH, et al. ADHD and cannabis use in young adults examined using fMRI of a Go/NoGo task. Brain Imaging Behav. 2016;10:761–71. doi:10.1007/s11682-015-9438-9.
   PubMed Web of Science ®Google Scholar
• Kelly C, Castellanos FX, Tomaselli O, Lisdahl K, Tamm L, Jernigan T, Newman E, Epstein JN, Molina BSG, Greenhill LL, et al. Distinct effects of childhood ADHD and cannabis use on brain functional architecture in young adults. NeuroImage Clin. 2017;13:188–200. doi:10.1016/j.nicl.2016.09.012.
   PubMed Web of Science ®Google Scholar
• Charach A, Yeung E, Climans T, Lillie E. Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses. J Am Acad Child Adolesc Psychiatry. 2011;50:9–21. doi:10.1016/j.jaac.2010.09.019.
   PubMed Web of Science ®Google Scholar
• Klein RG, Mannuzza S, Olazagasti MAR, Craig M, Hallahan B, Murphy C, Johnston P, Spain D, Gillan N, Brammer M, et al. Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later. Arch Gen Psychiatry. 2012;69:1295–303. doi:10.1001/archgenpsychiatry.2012.513.
   PubMed Web of Science ®Google Scholar
• Lee SS, Humphreys KL, Flory K, Liu R, Glass K. Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review. Clin Psychol Rev. 2011;31:328–41. doi:10.1016/j.cpr.2011.01.006.
   PubMed Web of Science ®Google Scholar
• Molina BSG, Hinshaw SP, Eugene Arnold L, Swanson JM, Pelham WE, Hechtman L, Hoza B, Epstein JN, Wigal T, Abikoff HB, et al. Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. J Am Acad Child Adolesc Psychiatry. 2013;52:250–63. doi:10.1016/j.jaac.2012.12.014.
   PubMed Web of Science ®Google Scholar
• Zamberletti E, Gabaglio M, Parolaro D. The endocannabinoid system and autism spectrum disorders: insights from animal models. Int J Mol Sci. 2017;18.
   PubMed Web of Science ®Google Scholar
• Karhson DS, Krasinska KM, Dallaire JA, Libove RA, Phillips JM, Chien AS, Garner JP, Hardan AY, Parker KJ. Plasma anandamide concentrations are lower in children with autism spectrum disorder. Mol Autism. 2018;9:18. doi:10.1186/s13229-018-0203-y.
   PubMed Web of Science ®Google Scholar
• Wei D, Lee D, Cox CD, Karsten CA, Peñagarikano O, Geschwind DH, Gall CM, Piomelli D. Endocannabinoid signaling mediates oxytocin-driven social reward. Proc Natl Acad Sci USA. 2015;112:14084–89. doi:10.1073/pnas.1509795112.
   PubMed Web of Science ®Google Scholar
• Gu B. Cannabidiol provides viable treatment opportunity for multiple neurological pathologies of autism spectrum disorder. Glob. Drugs Ther. Internet]. 2017 [cited 2019 Jun 10];2. Available from: http://www.oatext.com/cannabidiol-provides-viable-treatment-opportunity-for-multiple-neurological-pathologies-of-autism-spectrum-disorder.php
   PubMedGoogle Scholar
• Kaplan JS, Stella N, Catterall WA, Westenbroek RE. Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome. Proc Natl Acad Sci USA. 2017;114:11229–34. doi:10.1073/pnas.1711351114.
   PubMed Web of Science ®Google Scholar